Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


India’s DCGI, U.S. FDA Collaborate On Drug Rules

This article was originally published in PharmAsia News

Executive Summary

The Drug Controller General of India and its U.S. counterpart, FDA, are in discussions expected to lead to a stronger regulatory agency. The talks cover improved monitoring of drugs, regulations covering medical devices and rules governing clinical practices and biologics. The DCGI also has plans to inspect plants in other countries, such as China, where raw materials are made for export to Indian drug makers. A DCGI team visited the FDA's offices last month and the U.S. agency plans to open offices in three Indian cities. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts